Trav3d-2 Inhibitors
Trav3d-2 inhibitors are a specialized class of chemical compounds designed to specifically interact with the Trav3d-2 protein or receptor, inhibiting its biological activity by blocking or modulating its functional sites. These inhibitors typically bind to the active site of Trav3d-2, preventing the normal substrate or ligand from interacting with the protein, thereby disrupting its role in the corresponding biochemical pathway. In some cases, Trav3d-2 inhibitors can bind to allosteric sites-regions of the protein distinct from the active site-causing a conformational change that reduces or halts the protein's functional activity. The interaction between these inhibitors and Trav3d-2 is mediated by a variety of non-covalent forces, such as hydrogen bonds, van der Waals forces, ionic interactions, and hydrophobic contacts. The stability and specificity of this binding are crucial for the inhibitor's effectiveness, ensuring that the Trav3d-2 protein is sufficiently blocked from performing its natural role.
The structural diversity of Trav3d-2 inhibitors is a key factor in their ability to interact with the protein in specific and potent ways. These inhibitors can range from small, simple organic molecules to larger, more complex structures, depending on the design strategy. Key structural elements, such as aromatic rings, heterocycles, and functional groups like hydroxyl, amine, or carboxyl groups, contribute to the inhibitor's binding affinity and selectivity by allowing them to interact with both polar and non-polar regions of the Trav3d-2 protein. The physicochemical properties of these inhibitors-such as molecular weight, polarity, and lipophilicity-are carefully optimized to enhance their solubility, stability, and binding strength. Hydrophobic regions within the inhibitor structure may interact with non-polar pockets of the Trav3d-2 protein, while hydrophilic groups form hydrogen bonds or ionic interactions with polar residues. These properties are critical to designing effective inhibitors that can bind robustly to the Trav3d-2 protein while maintaining stability and functionality in a variety of biological environments.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including many that are upstream regulators of Trav3d-2. Inhibition of these kinases results in a downstream inhibition of Trav3d-2 activity due to disruption of its activation signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase inhibitor. By inhibiting PI3K, it disrupts the PI3K/AKT signaling pathway, which is necessary for the phosphorylation and activation of many proteins, including Trav3d-2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent and irreversible inhibitor of phosphoinositide 3-kinases. By inhibiting PI3K, it prevents the activation of downstream targets such as AKT, leading to reduced functional activity of Trav3d-2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. This pathway can be involved in the phosphorylation and activation of various proteins, potentially including Trav3d-2. Inhibition of MEK leads to decreased ERK activity and thus reduced Trav3d-2 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. The p38 MAP kinase pathway can influence various cellular processes, including the activity of proteins like Trav3d-2. Inhibition of p38 MAPK can thus indirectly lead to the inhibition of Trav3d-2 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, c-Jun N-terminal kinase. JNK is involved in regulatory processes that could affect the function of proteins such as Trav3d-2. By inhibiting JNK, SP600125 indirectly inhibits the activity of Trav3d-2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of the ERK pathway. This pathway is implicated in the regulation of a wide range of proteins, including Trav3d-2. MEK inhibition by U0126 leads to decreased ERK activity and reduced Trav3d-2 function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases can phosphorylate a variety of substrates, potentially including Trav3d-2. Inhibition of Src kinases by PP2 would impede Trav3d-2 activation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is an inhibitor of the EGFR and HER2/neu tyrosine kinases. If Trav3d-2 is downstream of these receptors, inhibition by Lapatinib would lead to decreased activation and function of Trav3d-2. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor and can affect protein degradation pathways. By altering protein turnover, Bortezomib could lead to the accumulation of regulatory proteins that inhibit Trav3d-2 activity. | ||||||